JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 180 filers reported holding JUNO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.57 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $65,481,000 | +32.8% | 1,432,527 | +30.4% | 0.02% | +21.1% |
| Q3 2017 | $49,295,000 | +127.8% | 1,098,861 | +51.8% | 0.02% | +111.1% |
| Q2 2017 | $21,642,000 | +14.5% | 724,074 | -15.0% | 0.01% | -10.0% |
| Q1 2017 | $18,901,000 | -35.7% | 851,775 | -45.4% | 0.01% | -33.3% |
| Q4 2016 | $29,410,000 | -13.2% | 1,560,262 | +38.3% | 0.02% | -6.2% |
| Q3 2016 | $33,863,000 | -4.5% | 1,128,389 | +22.4% | 0.02% | -15.8% |
| Q2 2016 | $35,445,000 | +18.6% | 922,072 | +17.5% | 0.02% | +18.8% |
| Q1 2016 | $29,893,000 | +9.8% | 784,796 | +26.8% | 0.02% | +33.3% |
| Q4 2015 | $27,216,000 | -45.9% | 618,959 | -49.9% | 0.01% | -45.5% |
| Q3 2015 | $50,269,000 | +77.1% | 1,235,416 | +132.1% | 0.02% | +83.3% |
| Q2 2015 | $28,389,000 | +32.6% | 532,318 | +50.8% | 0.01% | +20.0% |
| Q1 2015 | $21,410,000 | +8071.8% | 352,940 | +6934.9% | 0.01% | – |
| Q4 2014 | $262,000 | – | 5,017 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |